Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
- PMID: 32206190
- PMCID: PMC7075468
- DOI: 10.18632/oncotarget.27512
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
Abstract
[This corrects the article DOI: 10.18632/oncotarget.4318.].
Copyright: © 2020 Goldenberg et al.
Figures
Erratum for
-
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Oncotarget. 2015 Sep 8;6(26):22496-512. doi: 10.18632/oncotarget.4318. Oncotarget. 2015. PMID: 26101915 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous